Subacute thyroiditis

Summary

Subacute thyroiditis (MONDO:0006982) is a disease and 5 clinical trials. Top therapeutic interventions include prednisone and corticorelin. A subtype of acute thyroiditis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	subacute thyroiditis
Mondo ID	MONDO:0006982
EFO	EFO:1001194
MeSH	D013968
DOID	DOID:7165
ICD-10-CM	E06.1
ICD-11	1320394379
NCIT	C35071, C35828
SNOMED CT	428041004
UMLS	C0040149
MedGen	21549
MedDRA	10042298
Is cancer (heuristic)	no

Also known as: De Quervain thyroiditis · De Quervain’s thyroiditis · de Quervain’s thyroiditis · DeQuervain thyroiditis · giant-cell thyroiditis · granulomatous thyroiditis · Subacute granulomatous thyroiditis · Subacute thyroiditis

Disease family

This is a subtype of acute thyroiditis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › thyroid gland disorder › thyroiditis › acute thyroiditis › subacute thyroiditis

Related subtypes (1): subacute lymphocytic thyroiditis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cortisone Acetate	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)
Celecoxib	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE4	1
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01837433	PHASE4	COMPLETED	Short-term Prednisone to Treat STA Study(SPTSS)
NCT07571681	PHASE2/PHASE3	NOT_YET_RECRUITING	Colchicine for Autoimmune and Subacute Thyroiditis
NCT06285617	PHASE3	UNKNOWN	Short-Term Versus 6-Week Prednisone in The Treatment of Subacute Thyroiditis
NCT05070091	Not specified	COMPLETED	The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.
NCT06391515	Not specified	COMPLETED	Subacute Thyroiditis in the SARS-CoV-2 Era

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PREDNISONE	4	1
CORTICORELIN	3	1
CHEMBL15720	0	1